Streetbeat News

TWST

Twist Bioscience Corporation

https://www.twistbioscience.com

Industry

Medical - Diagnostics & Research

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Open

45.78

Mkt cap

2.7B

Volume

834K

High

46.82

P/E Ratio

-11.92

52-wk high

60.90

Low

45.32

Div yield

N/A

52-wk low

15.85

Scotiabank analyst Sung Ji Nam maintains a Sector Outperform rating on Twist Bioscience (TWST) and raises the price target from $30 to $43.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 6:18 pm

Twist Bioscience Corporation (NASDAQ:TWST) announced the early access of its Twist Flex Prep Ultra High-Throughput (UHT) Kit, designed to significantly reduce costs and increase efficiency in NGS workflows, particularly in agricultural genomics. The kit features novel Normalization By Ligation (NBL) technology for self-normalizing sample inputs, enhanced multiplexing capabilities, and compatibility with automation systems. This innovation is expected to accelerate NGS adoption in AgBio by offering a scalable, streamlined, and cost-effective solution. Twist Bioscience will showcase this technology at the AGBT General Meeting in Orlando, FL.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:24 pm

Twist Bioscience's stock is trading higher following the company's announcement of an increase in its fiscal year 2024 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 4:51 pm

Twist Bioscience anticipates Q2 FY24 sales to be between $70M-$71M, closely aligning with the consensus estimate of $70.01M. The company also projects a gross margin of 39% for the same period.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:42 pm

Twist Bioscience has revised its FY 2024 gross margin guidance upwards to 40%-41% from the previously expected 39%-40%.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:34 pm

Twist Bioscience has raised its FY24 revenue guidance to a range of $288M to $293M, up from the previous forecast of $285M to $290M. This new guidance surpasses the consensus estimate of $289.69M.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:34 pm

Twist Bioscience (NASDAQ:TWST) reported Q1 earnings with losses of $(0.75) per share, surpassing the $(0.78) estimate, and sales of $71.50M, exceeding the $67.58M estimate. This represents a 1.35% decrease in losses per share compared to last year, and a 31.81% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:31 pm

Earnings reports for February 2, 2024, include major companies across various sectors. Expectations include a mix of profits and losses, with significant revenues projected for companies like Exxon Mobil and Chevron. The diversity of sectors reporting may provide insights into broader economic trends.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 10:28 am

Twist Bioscience (NASDAQ:TWST) is scheduled to release its quarterly earnings report on 2024-02-02, with analysts expecting an EPS of $-0.78. The company's past performance shows a mixed impact on its stock price following earnings announcements, despite generally beating EPS estimates. Shares have risen 32.3% over the last 52 weeks, indicating a positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 3:01 pm

Barclays analyst Luke Sergott has maintained an Overweight rating on Twist Bioscience (NASDAQ:TWST) and increased the price target from $30 to $45.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:58 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.